Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They are moving in the right direction. Good news. I had some chat with Anne already this morning to get some more details and to understand int properly.
Looks like that in UK is an existing shortage of phlebotamists. GDBY is in a good position with its 90 locations which are currently offering this service including finger prick and venous blood draws.
The mentioned providers will use this service from GDBY to get their blood testing sold to the public. GDBY gets paid for the service offer (like a NaaS solution) and gets a fee per done test. The provider will take the lab costs for those done test.
At the end GDBY is able to increase their revenues and in parallel they will reduce there costs.
It helps to fill the unused potential of the netwrok. More to come.
If this is just the start what is coming next? Clearly sitting on more projects
maybe more providers. maybe NHS trial participation.
nobody knows
They are moving really slowly.
I think next will be fins and hopefully a new investor deck which shows a more realistic outlook than the presentation before.
Still fingers cross that they cann sign some more partners for the GDBY phlebotomist service. Becoming partner of some insurances would also be nice. I'm still hoping for some moves from the NHS to shift services into the private sector.
I am sure that with the Q1 slide deck reveal there will be big announcements. They are very good at diversifying. The clinics numbers have dwindled further which they seemed to have stopped pushing. George seems very confident for the year ahead so there will be a solid plan. Not so sure about the share price though. It is on the floor at the minute. Extremely disappointed with Geremy for that. He tells long term holders to hang on in there and then steps back from his role as Exec. Very poor.
It seems to have been planned for a long time that Geremy would step down as CEO.
The number of clinics has been reduced somewhat. There are currently 232 locations. Of these, 138 offer venous draw blood tests. 54 are from Superdrug. So there is still a potential of 94 clinics to roll out the blood tests without having to add new ones.
If we review the figures puroprted in the current investment slide deck they are way wide of the mark. We need more realistic expectations. Geremy has stepped away once before only to return. I don't think he will return again now that George is CEO. I am confident that George will make a great success of the business but it will be a long time before any of us see the benefit of that. Love hemp story is real shame for investors
https://www.investegate.co.uk/yooma-wellness-inc.--yoom-/rns/operational-update/202302100700045144P/
Another one